Although discussion continues about whether PD-L1 tumor expression evaluation is a useful predictive biomarker in response to PD-1/PD-L1 inhibitors, several recent studies in humans and dogs have corroborated its use [46,68,69,70]. This evidence concerns the gene PDCD1 and neoplasm.